Item 8.01. Other Events.
The information in this Current Report is being furnished and shall not be
deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that Section. The
information in this Current Report shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act of
1933, as amended, except as shall be expressly set forth by specific reference
in such filing.
Theravance Biopharma, Inc. (the "Company") is announcing that it has voluntarily
discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK
inhibitor for inflammatory intestinal diseases) in Crohn's disease (Study 0173).
The Company's decision was made following the planned review of trial data by
the independent data monitoring committee who determined that, while there are
no safety concerns, there are concerns about the ongoing benefit-risk of
continuing the trial, and the committee recommended the sponsor discontinue the
study. The Company has made the decision to discontinue the study.
© Edgar Online, source Glimpses